PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.\', \'Kunming University of Science and Technology Library, Kunming, China.\', \'Technology Centre, Guangzhou Customs, Guangzhou, China.\', \'Jilin Yatai Chinese Medicine Development Institute, Changchun, Jilin, China.\', \'State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China; State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, China; KingMed Virology Diagnostic & Translational Center, Guangzhou, China. Electronic address: jeffyah@163.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0944-7113(20)30128-810.1016/j.phymed.2020.153296
?:doi
?:hasPublicationType
?:journal
  • Phytomedicine : international journal of phytotherapy and phytopharmacology
is ?:pmid of
?:pmid
?:pmid
  • 32890913
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all